Allianz Asset Management
CBAY

Allianz Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Allianz Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-69,890
Closed -$358K – 2873
2019
Q3 		$358K Sell
69,890
-114,647
-62% -$694K ﹤0.01% 2476
2019
Q2 		$1.32M Buy
184,537
+1,370
+0.7% +$15.5K ﹤0.01% 2041
2019
Q1 		$2.43M Sell
183,167
-13,505
-7% -$144K ﹤0.01% 1776
2018
Q4 		$1.55M Sell
196,672
-13,311
-6% -$127K ﹤0.01% 1858
2018
Q3 		$2.33M Buy
209,983
+19,238
+10% +$239K ﹤0.01% 1879
2018
Q2 		$2.56M Buy
190,745
+63,787
+50% +$798K ﹤0.01% 1833
2018
Q1 		$1.65M Buy
126,958
+7,949
+7% +$98.8K ﹤0.01% 2011
2017
Q4 		$1.09M Buy
+119,009
New +$1.02M ﹤0.01% 2214

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Allianz Asset Management's CBAY Position: Q4 2019 in Review

Allianz Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 69,890 shares — an estimated $358K sold.

Allianz Asset Management first reported a position in CBAY in Q4 2017 and held it in 8 quarters. The position peaked at $2.56M in Q2 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

  • Allianz Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Allianz Asset Management sold 69,890 Cymabay Therapeutics shares in Q4 2019, an estimated $358K.
  • Allianz Asset Management first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 8 quarters.
  • Allianz Asset Management's Cymabay Therapeutics position peaked at $2.56M in Q2 2018.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Allianz Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.